Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...

Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I ...

Good morning, thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's call are David Ricks ...

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

US President Donald Trump has signalled plans to impose a 25% tariff on car imports, along with similar or higher levies on ...

WEC Energy Group, Inc. ( NYSE: WEC) Q4 2024 Earnings Conference Call February 4, 2025 2:00 PM ET Scott Lauber - President and Chief Executive Officer Xia Liu - Chief Financial Officer ...

Eli Lilly also forecast annual profit ... track in terms of its growth and outlook," he said. Investors had said they were keen to hear Lilly's plans for international growth and how it can ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the details for Canadian investors. Canada Goose Holdings Inc.’s third ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...